NASDAQ:TSRO - TESARO Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TESARO Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $74.96 0.00 (0.00 %) (As of 01/18/2019) Add Compare Today's Range$74.94Now: $74.96▼$74.9750-Day Range N/A52-Week Range$23.41Now: $74.96▼$75.16Volume1.19 million shsAverage Volume1.97 million shsMarket Capitalization$4.13 billionP/E RatioN/ADividend YieldN/ABeta0.38 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:TSRO Previous Symbol CUSIP88156910 CIK1491576 Webhttp://www.tesarobio.com/ Phone339-970-0900Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio2.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$223.33 million Price / Sales18.48 Cash FlowN/A Price / Cash FlowN/A Book Value$4.58 per share Price / Book16.37Profitability EPS (Most Recent Fiscal Year)($9.17) Net Income$-496,120,000.00 Net Margins-295.67% Return on Equity-1,209.72% Return on Assets-83.34%Miscellaneous EmployeesN/A Outstanding Shares55,050,000Market Cap$4.13 billion Next Earnings DateN/A OptionableOptionable Receive TSRO News and Ratings via Email Sign-up to receive the latest news and ratings for TSRO and its competitors with MarketBeat's FREE daily newsletter. TESARO (NASDAQ:TSRO) Frequently Asked Questions What is TESARO's stock symbol? TESARO trades on the NASDAQ under the ticker symbol "TSRO." How were TESARO's earnings last quarter? TESARO Inc (NASDAQ:TSRO) announced its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($3.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.66) by $0.38. The biopharmaceutical company earned $57.21 million during the quarter, compared to analysts' expectations of $65.50 million. TESARO had a negative net margin of 295.67% and a negative return on equity of 1,209.72%. TESARO's revenue for the quarter was up 94.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.82) EPS. View TESARO's Earnings History. Has TESARO been receiving favorable news coverage? Media headlines about TSRO stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. TESARO earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for TESARO. Who are some of TESARO's key competitors? Some companies that are related to TESARO include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of TESARO own? Based on aggregate information from My MarketBeat watchlists, some companies that other TESARO investors own include NVIDIA (NVDA), Clovis Oncology (CLVS), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Exelixis (EXEL), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT) and Ionis Pharmaceuticals (IONS). Who are TESARO's key executives? TESARO's management team includes the folowing people: Mr. Leon O. Moulder Jr., Co-Founder, CEO & Director (Age 62)Dr. Mary Lynne Hedley Ph.D., Co-Founder, Pres, COO & Director (Age 56)Mr. Timothy R. Pearson, Exec. VP & CFO (Age 51)Dr. Martin H. Huber Jr., Sr. VP & Chief Medical Officer (Age 59)Mr. Orlando Oliveira, Sr. VP & GM of International (Age 43) What is TESARO's stock price today? One share of TSRO stock can currently be purchased for approximately $74.96. How big of a company is TESARO? TESARO has a market capitalization of $4.13 billion and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis. View Additional Information About TESARO. What is TESARO's official website? The official website for TESARO is http://www.tesarobio.com/. How can I contact TESARO? TESARO's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900. MarketBeat Community Rating for TESARO (NASDAQ TSRO)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 643 (Vote Outperform)Underperform Votes: 505 (Vote Underperform)Total Votes: 1,148MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe TSRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2020 by MarketBeat.com StaffFeatured Article: Trading Stocks - What are percentage gainers?
